Home  »  Stocks to Invest   »  Advaxis Inc. (ADXS) stock plunges in the current m...

Advaxis Inc. (ADXS) stock plunges in the current market trading. Here’s to know why?

Advaxis Inc. (ADXS) stock decline by 10.09% in the current market trading after ADXS announced that it has signed a definitive agreement with two healthcare institutional investors. Advaxis, Inc. is a clinical-stage biotechnology company that develops and sells patented Lm-based antigen delivery drugs. These immunotherapies are focused on a framework technology that uses Listeria monocytogenes (Lm) that have been bioengineered to secrete antigen/adjuvant fusion proteins.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


What is happening?

On April 12, 2021 ADXS announced it has signed definitive agreements with two institutional investors who are working on healthcare for the purchase of

  • 17,577,400 shares of common stock
  • 7,671,937 pre-funded warrants to buy 7,671,937 shares of common stock
  • And also the registered common share purchase warrants to purchase 11,244,135 shares of common stock.

In a separate private placement, ADXS has agreed to grant unregistered common share purchase warrants to the investors to acquire 14,005,202 shares of ADXS’s common stock. Following a registered direct offering, priced at the market under NASDAQ rules, each share of common stock and associated common share purchase warrant are being offered together at a joint offering price of $0.7921, and each Pre-funded Warrant and accompanying common warrant are being sold together at a joint offering price of $0.7911. The Pre-Funded Warrants are automatically exercisable at a price of $0.001 and can be exercised in whole or in part before all of the Pre-Funded Warrants have been exercised.

The exercise price of the registered common share purchase warrants will be $0.70 per share, they will be automatically payable, and they will expire five (5) years from the date of grant. The unregistered common share purchase warrants will have an exercise price of $0.70 per share, will be exercisable fourteen days after the Company raises its approved share capital, and will expire five (5) years after they are issued.


ADXS has planned to use the funds from the offering to finance ADXS’s ongoing research and development activities in conjunction with increasing its product pipeline, including but not limited to investment in its ADXS-HOT program, as well as for general corporate purposes. A part of the net proceeds can also be used to purchase or invest in other companies, products, or technologies. The Offering’s exclusive placement agent is A.G.P./Alliance Global Partners.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam